share_log

Lotus Health Group (SHSE:600186) Delivers Shareholders Impressive 22% CAGR Over 5 Years, Surging 5.5% in the Last Week Alone

Lotus Health Group (SHSE:600186) Delivers Shareholders Impressive 22% CAGR Over 5 Years, Surging 5.5% in the Last Week Alone

莲花健康集团(SHSE: 600186)在5年内为股东带来了令人印象深刻的22%的复合年增长率,仅在上周就飙升了5.5%
Simply Wall St ·  02/19 17:21

Lotus Health Group Company (SHSE:600186) shareholders might understandably be very concerned that the share price has dropped 38% in the last quarter. But in stark contrast, the returns over the last half decade have impressed. It's fair to say most would be happy with 172% the gain in that time. To some, the recent pullback wouldn't be surprising after such a fast rise. The more important question is whether the stock is too cheap or too expensive today.

莲花健康集团公司(SHSE: 600186)的股东可能会非常担心上个季度股价下跌了38%,这是可以理解的。但与之形成鲜明对比的是,过去五年的回报给人留下了深刻的印象。可以公平地说,大多数人会对那段时间内的172%的涨幅感到满意。对某些人来说,在如此快速的上涨之后,最近的回调并不奇怪。更重要的问题是今天的股票是太便宜还是太昂贵。

Since it's been a strong week for Lotus Health Group shareholders, let's have a look at trend of the longer term fundamentals.

由于对于Lotus Health Group的股东来说,这是表现强劲的一周,让我们来看看长期基本面的走势。

We don't think that Lotus Health Group's modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.

我们认为,莲花健康集团过去十二个月的微薄利润目前并未引起市场的充分关注。我们认为收入可能是更好的指导。总的来说,我们会将这样的股票与亏损公司一起考虑,这仅仅是因为利润量太低了。要使股东有信心公司大幅增加利润,就必须增加收入。

For the last half decade, Lotus Health Group can boast revenue growth at a rate of 0.7% per year. That's not a very high growth rate considering the bottom line. So we wouldn't have expected to see the share price to have lifted 22% for each year during that time, but that's what happened. Shareholders should be pretty happy with that, although interested investors might want to examine the financial data more closely to see if the gains are really justified. Some might suggest that the sentiment around the stock is rather positive.

在过去的五年中,莲花健康集团可以以每年0.7%的速度实现收入增长。考虑到底线,这不是一个很高的增长率。因此,我们没想到在此期间股价每年上涨22%,但事实就是这样。股东应该对此感到非常满意,尽管感兴趣的投资者可能希望更仔细地研究财务数据,看看收益是否真的合理。有人可能会认为,围绕该股的情绪相当乐观。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下图描述了收入和收入随时间推移而发生的变化(点击图片即可显示确切的数值)。

earnings-and-revenue-growth
SHSE:600186 Earnings and Revenue Growth February 19th 2024
SHSE: 600186 收益和收入增长 2024 年 2 月 19 日

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. This free interactive report on Lotus Health Group's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

我们很高兴地向大家报告,首席执行官的薪酬比资本相似公司的大多数首席执行官要适中。始终值得关注首席执行官的薪酬,但更重要的问题是公司多年来是否会增加收益。如果你想进一步调查该股,这份关于莲花健康集团收益、收入和现金流的免费互动报告是一个很好的起点。

A Different Perspective

不同的视角

It's nice to see that Lotus Health Group shareholders have received a total shareholder return of 58% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 22% per year), it would seem that the stock's performance has improved in recent times. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 2 warning signs we've spotted with Lotus Health Group .

很高兴看到莲花健康集团的股东在过去一年中获得了58%的总股东回报率。由于一年期股东总回报率好于五年期股东总回报率(后者为每年22%),因此该股的表现似乎在最近有所改善。持乐观态度的人可能会将最近股东总回报率的改善视为业务本身随着时间的推移而变得更好。我发现将长期股价视为业务绩效的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。为此,你应该注意我们在莲花健康集团发现的两个警告信号。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,请看一下我们预计收益将增加的这份免费公司名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发